713 results on '"Biganzoli, Laura"'
Search Results
2. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
3. EUSOMA quality indicators for non-metastatic breast cancer: An update
4. European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care
5. Sensitive tumor detection, accurate quantification, and cancer subtype classification using low-pass whole methylome sequencing of plasma DNA
6. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
7. Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.
8. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres
9. PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
10. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial
11. Systemic Treatment of Metastatic Breast Cancer in Older Adults
12. A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer
13. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)
14. EUSOMA quality indicators for non-metastatic breast cancer: An update
15. Clinical trials in older patients with cancer : typical challenges, possible solutions, and a paradigm of study design in breast cancer
16. Adjuvant Endocrine Therapy
17. A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments
18. Metal recovery from incineration bottom ash: State-of-the-art and recent developments
19. The requirements of a specialist breast centre
20. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
21. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
22. EUSOMA quality indicators for non-metastatic breast cancer: An update
23. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
24. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
25. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology
26. Fertility Preservation in Women with Breast Cancer
27. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice
28. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
29. IN34 OPTIMAL MANAGEMENT OF AN OLDER FRAIL PATIENT WITH ADVANCED BREAST CANCER
30. Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings
31. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)
32. Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper
33. Intermediate Bulk Containers Re-use in the Circular Economy: An LCA Evaluation
34. LCA evaluation of packaging re-use: the steel drums case study
35. Packaging re-use: a starting point for its quantification
36. Quality indicators in breast cancer care: An update from the EUSOMA working group
37. Controversial issues in the management of older adults with early breast cancer
38. Chronic Conditions and Cancer in Older Adults
39. De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer
40. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
41. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
42. Supplemental Table S1 from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
43. Supplementary Figure Legend from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
44. Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
45. Supplementary figure S3 from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
46. Supplementary Figure 1B from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
47. Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
48. Supplementary Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
49. Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
50. Supplementary Figure 2 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.